Structured Abstract

Contents

• Acknowledgements
• Abbreviations
• 1. Purpose of the guidance document
• 2. Background
  • 2.1 HSS among pregnant women
  • 2.2 Ethical considerations associated with UAT-based ANC HSS
  • 2.3 PMTCT programmes in the context of HSS
  • 2.4 Early assessments of the utility of PMTCT programme data for HSS
• 3. Overview of assessing the utility of PMTCT programme data for surveillance
  • 3.1 Elements of a PMTCT surveillance assessment
  • 3.2 Deciding to conduct a PMTCT surveillance assessment
  • 3.3 Preparing to conduct a PMTCT surveillance assessment
• 4. Assessment activity A: Routine ANC HSS with PMTCT HIV testing variables added to the ANC HSS data collection form
  • 4.1 Comparison of HIV test results from ANC HSS and PMTCT programme data
• 5. Assessment activity B: Data quality assessment of PMTCT programme data and recording pratices at ANC HSS sites
  • 5.1 Variables of interest for assessing PMTCT programme data quality
  • 5.2 Methods for assessing PMTCT programme data through a DQA
  • 5.3 Analysis of data derived from a DQA of PMTCT data
• 6. Assessment activity C: Quality assurance assessment of PMTCT HIV testing at ANC HSS sites
  • 6.1 Data collection for a QA assessment of PMTCT HIV testing
  • 6.2 Analysis of data derived from a QA assessment of PMTCT HIV testing
• 7. Other issues when considering PMTCT-based HSS
  • 7.1 Economic assessment through top–down cost assessment
  • 7.2 PMTCT-based HSS in the context of other surveillance systems
• 8. Ethical considerations for implementing a PMTCT surveillance assessment
• 9. Next steps
• Appendix A Summary of published findings of studies assessing the utility of PMTCT data for surveillance
• Appendix B Sample ANC HSS data collection form with additional PMTCT HIV testing variables
• Appendix C Statistical appendix
• Appendix D Quality assessment of PMTCT data: sample site assessment tool
• Appendix E Sample quality assurance checklist for PMTCT HIV testing
• References

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the report of the UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance and does not necessarily represent the decisions or policies of the World Health Organization.